‘Hard To Lose’ Mutations In Tumors May Predict Response To Immunotherapy

‘Hard To Lose’ Mutations In Tumors May Predict Response To Immunotherapy

Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient’s response to immunotherapy. Now, Johns Hopkins investigators have found that a subset of mutations within the overall TMB, termed “persistent mutations,” are less likely to be edited out as cancer evolves, rendering tumors more likely to respond to immunotherapy. Read more here.

SEE ALL NEWS
Recent Posts
Reduce Your Breast Cancer Risk Novel Blood Test May Detect Cancer Stress Busters: 4 Integrative Treatments Mammogram Age Guidelines: What You Need to Know Transcription Factors Contribute to Subtypes of Colorectal Cancers Johns Hopkins Hepatologists Detect Liver Cancer in Urine Test Johns Hopkins Surgeons Pioneer Combination of Procedures for Patients with Advanced Colorectal Cancer How to Make a Healthy Smoothie Scientists Design a Nanoparticle That May Improve mRNA Cancer Vaccines